Elo Mutual Pension Insurance Co Increases Stake in Hologic, Inc. (NASDAQ:HOLX)

Elo Mutual Pension Insurance Co grew its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 25.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,888 shares of the medical equipment provider's stock after purchasing an additional 5,197 shares during the period. Elo Mutual Pension Insurance Co's holdings in Hologic were worth $1,866,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of HOLX. State Street Corp raised its stake in Hologic by 0.8% during the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider's stock valued at $847,944,000 after buying an additional 81,057 shares during the last quarter. FMR LLC increased its holdings in Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock valued at $453,940,000 after buying an additional 2,174,093 shares during the last quarter. Victory Capital Management Inc. raised its position in Hologic by 0.5% in the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider's stock worth $354,506,000 after acquiring an additional 24,358 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Hologic by 3.0% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider's stock worth $322,272,000 after acquiring an additional 129,035 shares during the last quarter. Finally, Boston Partners grew its position in shares of Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after acquiring an additional 1,602,463 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Remove Ads

Hologic Price Performance

Hologic stock traded down $0.32 during midday trading on Thursday, reaching $60.24. 472,263 shares of the stock traded hands, compared to its average volume of 1,805,763. The stock has a market cap of $13.52 billion, a P/E ratio of 19.00, a PEG ratio of 2.14 and a beta of 0.97. The stock's fifty day moving average is $64.69 and its 200-day moving average is $72.88. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12 month low of $58.38 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

HOLX has been the subject of a number of analyst reports. Argus cut Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Jefferies Financial Group initiated coverage on shares of Hologic in a research report on Tuesday, December 10th. They issued a "hold" rating and a $85.00 price target for the company. Finally, Stephens restated an "overweight" rating and set a $84.00 price objective on shares of Hologic in a research report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.